Phase 1 completion is not happening in the US, it’s in Australia and AGN is a direct comparison to NYR
R&D rebate gets announced this month and tops them up around 2 million dollars in the bank. They will have 6-7 million dollars in September leading into phase 1. They are fully funded to phase 2 preparations and FDA submission for phase 2.
NYR only needs to prove it’s safe. AGN has done all the heavy lifting in the mechanism of action and efficacy. If you did any research AGN and NYR work by reducing calcium influx in the cell. AGN has already proven up that NYR works as their mechanism of action targets the same receptors
- Forums
- ASX - By Stock
- Ann: Brain Injury Program GLP Studies Further Update
NYR
nyrada inc.
Add to My Watchlist
0.00%
!
23.5¢

Phase 1 completion is not happening in the US, it’s in Australia...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
23.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $49.56M |
Open | High | Low | Value | Volume |
23.5¢ | 26.5¢ | 23.5¢ | $218.5K | 892.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 250000 | 23.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
24.0¢ | 47500 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 250000 | 0.230 |
5 | 88773 | 0.220 |
2 | 120005 | 0.215 |
2 | 110000 | 0.210 |
5 | 269378 | 0.200 |
Price($) | Vol. | No. |
---|---|---|
0.240 | 47500 | 2 |
0.245 | 43000 | 3 |
0.255 | 3407 | 1 |
0.260 | 4500 | 1 |
0.265 | 49139 | 1 |
Last trade - 12.07pm 18/06/2025 (20 minute delay) ? |
Featured News
NYR (ASX) Chart |
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online